2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow Sells 2,298 Shares

2seventy bio, Inc. (NASDAQ:TSVT) COO Jessica Snow sold 2,298 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $4.95, for a total value of $11,375.10. Following the completion of the sale, the chief operating officer now owns 254,193 shares of the company’s stock, valued at approximately $1,258,255.35. This trade represents a 0.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

2seventy bio Price Performance

TSVT stock remained flat at $4.96 during midday trading on Wednesday. The company had a trading volume of 468,446 shares, compared to its average volume of 620,134. 2seventy bio, Inc. has a 52-week low of $2.29 and a 52-week high of $5.99. The stock’s 50 day simple moving average is $2.85 and its 200-day simple moving average is $3.69. The firm has a market capitalization of $255.88 million, a price-to-earnings ratio of -2.67 and a beta of 1.73.

Institutional Trading of 2seventy bio

Institutional investors have recently made changes to their positions in the business. Erste Asset Management GmbH acquired a new position in 2seventy bio in the third quarter worth about $25,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of 2seventy bio in the 4th quarter worth approximately $32,000. BNP Paribas Financial Markets bought a new position in shares of 2seventy bio during the 4th quarter worth approximately $35,000. ProShare Advisors LLC bought a new stake in shares of 2seventy bio during the 4th quarter valued at $48,000. Finally, Raymond James Financial Inc. acquired a new position in shares of 2seventy bio in the 4th quarter valued at $52,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on TSVT. Leerink Partners restated a “market perform” rating and issued a $5.00 price objective (down from $9.00) on shares of 2seventy bio in a research note on Tuesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. Morgan Stanley cut their price objective on 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Friday, March 14th. Finally, Leerink Partnrs lowered 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $6.67.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.